Olmesartan Medoxomil

An Olmesartan Medoxomil is an Angiotensin II Receptor Blocker that is structurally characterized as a prodrug.

• Context:
  • It can be chemically described as a Benzimidazole Derivative.
  • It can be hydrolyzed to its active metabolite, olmesartan, in the gastrointestinal tract.
  • It can have a selective and competitive antagonism of the Angiotensin II Type 1 Receptor.
  • It can be more lipid-soluble than other ARBs, influencing its absorption and plasma concentration.
  • It can exhibit a high affinity for the AT1 receptor subtype, which is responsible for the blood pressure-lowering effect.
  • It can have a molecular formula of C29H30N6O6 and a molecular weight of 558.59 g/mol.
  • It can be insoluble in water but soluble in dimethyl sulfoxide and methanol.
  • It can have a half-life of approximately 13 hours, contributing to its once-daily dosing regimen.
  • ...
• Example(s):
  • Benicar,
  • ...
• Counter-Example(s):
  • Candesartan,
  • Irbesartan,
  • Telmisartan.
• See: Bile Duct, Valsartan, By Mouth, Diuretics, Amlodipine, Liver, Kidney, Medication, Hypertension, by Mouth, Olmesartan/Hydrochlorothiazide, [[Olmesartan/A

---

---

References

2024

• (Wikipedia, 2024) ⇒ https://en.wikipedia.org/wiki/Olmesartan Retrieved:2024-2-6.
  • Olmesartan, sold under the brand name Benicar among others, is a medication used to treat high blood pressure (hypertension). It is taken by mouth. Versions are available as the combination olmesartan/hydrochlorothiazide and olmesartan/amlodipine.

    Common side effects include dizziness, headaches, diarrhea, and back pain. Serious side effects may include kidney problems, low blood pressure, and angioedema. Use in pregnancy may harm the fetus and use when breastfeeding is not recommended. It is an angiotensin II receptor antagonist and works by blocking the effects of angiotensin II.

    It was patented in 1991 and came into medical use in 2002. It is available as a generic medication. In 2020, it was the 139th most commonly prescribed medication in the United States, with more than 4million prescriptions, ranking 3rd among ARB's after Losartan (9th overall) and Valsartan (123rd overall).

---